Global pMDI Use and the Potential Impact of European PFAS Legislation on Access to These Essential Inhaled Medications
Janwillem W H Kocks, Tim Harrison, John P Bell, Andy Rignall, Mina Khezrian, Omar S Usmani · 2026
Read Global pMDI Use and the Potential Impact of European PFAS Legislation on Access to These Essential Inhaled Medications by Janwillem W H Kocks, Tim Harrison, John P Bell, Andy Rignall, Mina Khezrian, Omar S Usmani (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13287505.txt.
Description
Janwillem W H Kocks and co-authors counted inhaler sales in 2026 across 60 countries to judge how much patients rely on pressurised metered-dose inhalers, the familiar puffer devices. Sales records from 2013 to 2022 were converted into shares of all inhaler use, broken down by single puffs.
Puffers made up 77.3% of inhaler use in 2022 and led in almost every country studied. An estimated 8.1 million patients in the European Union used one for daily maintenance that year. Climate rules will retire current propellant gases, and a proposed chemical ban could also bite. The authors urge safeguards so green switches do not cut patient access.
Catalog record
| CREATOR | Janwillem W H Kocks, Tim Harrison, John P Bell, Andy Rignall, Mina Khezrian, Omar S Usmani |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 31299 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |